Theravance Biopharma settles YUPELRI patent litigation; Qilu generic entry delayed until April 2039

Theravance Biopharma, Inc.

Settlement resolves Hatch-Waxman patent litigation over YUPELRI (revefenacin) with Qilu.
Qilu granted royalty-free license to market generic revfenacin on or after April 23, 2039.
Settlement subject to review by U.S. DOJ and FTC as required by law.
Patent litigation against three other ANDA filers (Cipla, Eugia, Mankind) remains pending.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.